Lipidor presents updated project plan – initiates Phase III study of AKP02 in-house

In light of the company's successful Phase III study of calcipotriol spray (AKP01) against mild to moderate plaque psoriasis and subsequent discussions with pharmaceutical companies, the Board of Lipidor submits an updated project plan together with prioritization of the company's project portfolio.In January 2020, Lipidor announced positive results from the completed Phase III study of calcipotriol spray (AKP01) against mild to moderate plaque psoriasis. Discussions with medium and large pharmaceutical companies regarding the licensing, marketing and sale of a product based on AKP01 have